Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


02.06.23 / Tradegate WKN: A1XF0S / Symbol: AKBA / Name: Akebia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Akebia Therapeutics Inc. Stock

There is an upward development for Akebia Therapeutics Inc. compared to yesterday, with an increase of €0.022 (2.180%).
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.

Pros and Cons of Akebia Therapeutics Inc. in the next few years

S********** s********
G***** c******* t* c**********
W********* I********* f** t** n*** y****
C******** o* t** e**********
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Akebia Therapeutics Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Akebia Therapeutics Inc. 2.180% -2.476% 28.000% 208.434% 119.366% -89.961% -
Brainstorm Cell -0.720% -0.725% -0.725% 1.182% 93.230% -61.135% -
Sorrento Therapeutics Inc. -24.520% 0.000% 0.000% -82.438% -65.296% -93.513% -
Concert Pharmaceuticals Inc. 0.180% 0.000% 0.000% - 56.305% - -


Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating.
Ratings data for AKBA provided by MarketBeat
Show more

Buy Akebia Therapeutics Inc.
Show more

Prediction Buy
Perf. (%) -37.12%
Target price 6.765
Ends at 30.10.19

Buy closed
Show more


Why Shares of Akebia Therapeutics Were Up Tuesday:
Why Shares of Akebia Therapeutics Were Up Tuesday

Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight